RVMD
Revolution Medicines, Inc.Healthcare · $43.1B market cap
Verdict
We can't put a fair value on RVMD right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.
Business quality
0 of 5 clear the 10% bar. What are the Big Five?
Follow RVMD
Track it on your watchlist and see the full analysis. Free.
Create a free accountInsider activity
Since Aug 31, 2026: no open-market purchases and 14 sales worth $15.0M. Why purchases matter
Sales
Kim Lorence H.
director · 2026-09-08
Sold
$79K
Kim Lorence H.
director · 2026-09-08
Sold
$812K
Kim Lorence H.
director · 2026-09-08
Sold
$996K
Kim Lorence H.
director · 2026-09-08
Sold
$598K
Kim Lorence H.
director · 2026-09-08
Sold
$748K
Show all 14 salesShow fewer
Kim Lorence H.
director · 2026-09-08
Sold
$207K
Kim Lorence H.
director · 2026-09-08
Sold
$146K
Kim Lorence H.
director · 2026-08-31
Sold
$129K
Kim Lorence H.
director · 2026-08-31
Sold
$437K
Kim Lorence H.
director · 2026-08-31
Sold
$1.5M
Kim Lorence H.
director · 2026-08-31
Sold
$5.3M
Kim Lorence H.
director · 2026-08-31
Sold
$2.6M
Kim Lorence H.
director · 2026-08-31
Sold
$1.3M
Kim Lorence H.
director · 2026-08-31
Sold
$60K
About Revolution Medicines, Inc.
Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The…
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works